David Grainger, Medicxi

David Grainger is a co-founder and Venture Partner at Medicxi. See contact routes.

About David Grainger

David Grainger is a co-founder and Venture Partner at Medicxi, a European venture capital firm that invests in early-stage life sciences companies, specifically in biotechnology developing innovative therapeutics for oncology, immunology, rare diseases, and infectious diseases. He has led investments in notable portfolio companies such as Padlock Therapeutics (acquired by Bristol-Myers Squibb) and co-founded XO1 (acquired by Janssen Pharmaceuticals), while also serving as Chairman for Z-Factor and Morphogen-IX. Grainger’s distinctive thesis centers on the “Impatient Capital Model,” which emphasizes rigorous experimental validation and capital efficiency to rapidly turn early-stage science into drug candidates and startups.

David Grainger at a glance

Role
Managing Director
Organization
Medicxi
Location
London, England, United Kingdom
Investor type
Venture Capital

Frequently asked about David Grainger

What does David Grainger invest in?
We have not verified a stated sector or stage focus for David Grainger at Medicxi (London, England, United Kingdom). The profile lists the organization, location and investors we track alongside them.
How do I contact David Grainger?
David Grainger's published profile links (website, LinkedIn or X where available) are listed on the StartupFundraising.com investor profile.
Where is David Grainger based?
David Grainger is based in London, England, United Kingdom.

This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in London.

Investors similar to David Grainger (20)

Browse related investor lists (2)

Compare David Grainger (8)

Investors like David Grainger · Full investor directory · Investor access · Company funding database